Fore score

How Cerecor's forebrain-specific GRIA antagonist sidelines GRIA's side effects

Cerecor Inc. (NASDAQ:CERC) has picked up a forebrain-selective anti-epileptic compound from Eli Lilly and Co. (NYSE:LLY) that could treat seizures by blocking AMPA glutamate receptor (GRIA; GLUR) without the dose-limiting motor side effects associated with that target.

Cerecor added CERC-611 - formerly LY3130418 - to its arsenal of neurological programs in an October deal with Lilly. Last month in Nature Medicine, Lilly researchers reported the compound

Read the full 659 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers